Web16 okt. 2024 · D-norpseudoephedrine (NPE), also known as cathine, is found naturally in the shrub Catha edulis “Khat.” NPE has been widely used as an appetite suppressant for the treatment of obesity. Although it is known that NPE acts on α1-adrenergic receptors, there is little information about the role of dopamine receptors on NPE’s induced anorectic and … Web25 jun. 2024 · PRESS RELEASE June 25, 2024 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its partner Productos Medix, S.A de S.V, (Medix) has provided Saniona with an update on the Mexican regulatory authority Comisión Federal para la Protección contra RiesgosSanitarios …
Saniona AB: Saniona
Web1 feb. 2024 · February 1, 2024. Saniona, a leading biotech company in the field of ion channels, today announced that its partner in Mexico, Medix, has completed recruitment for its Phase 3 clinical study of tesofensine in obesity.The trial is expected to be completed in 2024 and topline data is expected by early 2024. "Our collaboration with Medix … Web14 apr. 2024 · Tesofensine has shown outstanding weight loss in a phase 2 clinical study in obese persons. Tesofensine has been tested in more than 1,300 patients and was in general well tolerated. Therefore, tesofensine has the potential to become the preferred treatment option for an important health problem in Mexico," says Carlos López Patán, … hornets playoff tickets
Medix Seeks Approval of Tesofensine to Treat Obesity in Mexico
WebAfgørelsens time nærmer sig for Tesofensine, der i bedste fald kan være på markedet i Mexico fra næste år og dermed generere indtægter til Saniona. Godkendelse eller mangel på samme omkring Tesofensine er et afgørende punkt. Partneren Medix fastholder planen om at få fedmeproduktet Tesofensine på markedet i Mexico i løbet af 2024. Web25 jun. 2024 · PRESS RELEASE June 25, 2024 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its partner Productos Medix, S.A de S.V, (Medix) has provided Saniona with an update on the Mexican regulatory authority Comisión Federal para la Protección contra Riesgos Sanitarios … Web25 feb. 2024 · Medix licensed the rights to develop and commercialize tesofensine in Mexico and Argentina from Saniona in 2016, Medix has conducted a successful Phase 3 obesity study in Mexico. The top-line results were published in December 2024 and Medix filed for a market authorization in Mexico at the end of 2024. hornets playoff chances